GANX icon

Gain Therapeutics
GANX

Overview Fund Activity

24 hedge funds and large institutions have $5.68M invested in Gain Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.

Holders
24
Holders Change
+2
Holders Change %
+9.09%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
3
Closed
2
Calls
$331K
Puts
$128K
Net Calls
+$203K
Net Calls Change
-$75K

Top Buyers

1
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$313K
2
Geode Capital Management
2
Geode Capital Management
Massachusetts
$621K
3
Citadel Advisors
3
Citadel Advisors
Florida
$162K
4
RJA
4
Raymond James & Associates
Florida
$150K
5
Millennium Management
5
Millennium Management
New York
$56.3K

Top Sellers

1
Royal Bank of Canada
1
Royal Bank of Canada
Ontario, Canada
$90K
2
BCM
2
Bridgeway Capital Management
Texas
$207K
3
WAAG
3
Wealth Alliance Advisory Group
Kansas
$0
4
CC
4
Cannell Capital
Wyoming
$0
5
TRCT
5
Tower Research Capital (TRC)
New York
$19.5K
Name Market Value Shares Shares
Change 		Shares
Change %
CC
26
Cannell Capital
Wyoming
– – -12,371 Closed
Simplex Trading
27
Simplex Trading
Illinois
– – – –
CFGS
28
Concourse Financial Group Securities
Alabama
– – – –
1
2